Replies to post #10817 on Momenta Pharmaceuticals, Inc. (MNTA)

[Rocky3]

Unlike mL, if mC gets approved, MNTA will be a profitable company for years to come even if we have other approvals.

Wish I could be as certain as you on this topic. It seems to me that there clearly is a possibility of everything going against MNTA, so that it does not result in income.

1) Approval of another generic
2) Issuance of an authorized generic
3) Success of the conversion to 3 times a week of Cop
4) Much less market share for Cop due to market competition

If mCop ends up selling "only" $300-400MM annually (and it could be lower if there are several generics), it will be difficult to have enough income to cover much more than ongoing expenses (absent big revenue from Bax). So I surely do not expect the market to reward MNTA with the expectation of $2-4/sh income for "years to come" even if it is the only generic approved at the beginning. I can hope that it will happen, but then I hoped that it would happen with mLov.